Zegalogue approved in Europe

Zegalogue (dasiglucagon, Zealand Pharma) has been recommended by the European Medicines Agency (EMA) for the treatment of severe hypoglycemia in patients aged six years and older with diabetes.

Severe hypoglycemia is defined as having low blood glucose levels that requires assistance from another person to treat. However, the active substance of Zegalogue is dasiglucagon, a glycogenolytic hormone that increases blood glucose concentration by activating hepatic glucagon receptors. This stimulates glycogen breakdown and promotes the release of glucose from the liver.

The EMA’s Committee for Medicinal Products for Human Use (CHMP) based its decision on evidence from two studies involving adults and children aged 6 years or older with diabetes. These showed that treatment of insulin-induced hypoglycemia with Zegalogue reduced the time required to increase plasma glucose compared with placebo, with a median time to recovery of 10 minutes. More patients experienced plasma glucose recovery with Zegalogue compared with placebo, the CHMP said.

To find out more, CLICK HERE.


Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags